Goldman Sachs downgraded Baxter (BAX) to Neutral from Buy with a price target of $25, down from $37. The firm’s thesis on Baxter had centered on a recovery in the company’s IV therapies business following business disruption in 2024, a a cyclical margin recovery on waning inflationary pressures and improving mix, and deleveraging following the sale to the company’s dialysis business earlier this year, but based on year-to-date results, all of these factors look to be deferred, the analyst tells investors in a research note. The pace of margin expansion at Baxter is likely to progress at a more measured pace, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Cautious Outlook for Baxter International Amid Weaker MPT Performance and Revised Growth Expectations
- Baxter sees Q3 adjusted EPS 58c-62c, consensus 64c
- Baxter cuts FY25 adjusted EPS view to $2.42-$2.52 from $2.47-$2.55
- Baxter reports Q2 adjusted EPS 54c, consensus 61c
- BAX Earnings this Week: How Will it Perform?